97 related articles for article (PubMed ID: 21736867)
1. Idiotype immunization following high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma.
Holman PR; Costello C; deMagalhaes-Silverman M; Corringham S; Castro J; Ball ED
Biol Blood Marrow Transplant; 2012 Feb; 18(2):257-64. PubMed ID: 21736867
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma.
Laudi N; Arora M; Burns LJ; Miller JS; McGlave PB; Barker JN; Ramsay NK; Orchard PJ; Macmillan ML; Weisdorf DJ
Biol Blood Marrow Transplant; 2005 Feb; 11(2):129-35. PubMed ID: 15682074
[TBL] [Abstract][Full Text] [Related]
3. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
[TBL] [Abstract][Full Text] [Related]
4. Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma.
Andreadis C; Schuster SJ; Chong EA; Svoboda J; Luger SM; Porter DL; Tsai DE; Nasta SD; Elstrom RL; Goldstein SC; Downs LH; Mangan PA; Cunningham KA; Hummel KA; Gimotty PA; Siegel DL; Glatstein E; Stadtmauer EA
Bone Marrow Transplant; 2005 Dec; 36(11):955-61. PubMed ID: 16205727
[TBL] [Abstract][Full Text] [Related]
5. Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma.
Joao C; Porrata LF; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Gastineau DA; Markovic SN
Bone Marrow Transplant; 2006 May; 37(9):865-71. PubMed ID: 16532015
[TBL] [Abstract][Full Text] [Related]
6. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
van Imhoff GW; van der Holt B; Mackenzie MA; Van't Veer MB; Wijermans PW; Ossenkoppele GJ; Schouten HC; Sonneveld P; Steijaert MM; Kluin PM; Kluin-Nelemans HC; Verdonck LF;
J Clin Oncol; 2005 Jun; 23(16):3793-801. PubMed ID: 15809447
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy with rituximab/interleukin-2 after autologous stem cell transplantation as treatment for CD20+ non-Hodgkin's lymphoma.
Holmberg LA; Maloney D; Bensinger W
Clin Lymphoma Myeloma; 2006 Sep; 7(2):135-9. PubMed ID: 17026825
[TBL] [Abstract][Full Text] [Related]
8. Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma.
Cote GM; Hochberg EP; Muzikansky A; Hochberg FH; Drappatz J; McAfee SL; Batchelor TT; LaCasce AS; Fisher DC; Abramson JS; Armand P; Chen YB
Biol Blood Marrow Transplant; 2012 Jan; 18(1):76-83. PubMed ID: 21749848
[TBL] [Abstract][Full Text] [Related]
9. Autotransplantation for mantle cell lymphoma.
Vose JM
Cancer J; 2012; 18(5):427-31. PubMed ID: 23006947
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of tandem high-dose therapy with autologous stem cell support for adults with high-risk age-adjusted international prognostic index aggressive non-Hodgkin Lymphomas: a GOELAMS pilot study.
Monjanel H; Deconinck E; Perrodeau E; Gastinne T; Delwail V; Moreau A; François S; Berthou C; Gyan E; Milpied N;
Biol Blood Marrow Transplant; 2011 Jun; 17(6):935-40. PubMed ID: 21109011
[TBL] [Abstract][Full Text] [Related]
11. Conventional allograft and autograft in low grade lymphoma.
Avivi I; Goldstone AH
Best Pract Res Clin Haematol; 2005 Mar; 18(1):113-28. PubMed ID: 15694188
[TBL] [Abstract][Full Text] [Related]
12. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
Arranz R; Conde E; Grande C; Mateos MV; Gandarillas M; Albo C; Lahuerta JJ; Fernández-Rañada JM; Hernández MT; Alonso N; García Vela JA; Garzón S; Rodríguez J; Caballero D;
Eur J Haematol; 2008 Mar; 80(3):227-35. PubMed ID: 18088400
[TBL] [Abstract][Full Text] [Related]
13. Autologous transplantation in patients with relapsed or high-grade follicular lymphoma provides long term disease-free survival and best median duration of response.
Ganguly S; Divine CL; Deauna-Limayo D; Bodensteiner DC; Cook JD; Lewis JN; Skikne BS
Ann Hematol; 2005 Aug; 84(8):526-31. PubMed ID: 15915350
[TBL] [Abstract][Full Text] [Related]
14. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial.
Schouten HC; Qian W; Kvaloy S; Porcellini A; Hagberg H; Johnsen HE; Doorduijn JK; Sydes MR; Kvalheim G
J Clin Oncol; 2003 Nov; 21(21):3918-27. PubMed ID: 14517188
[TBL] [Abstract][Full Text] [Related]
15. Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC.
Touzeau C; Leux C; Bouabdallah R; Roussel M; Delarue R; Bouabdallah K; Thieblemont C; Cacheux V; Cartron G; Compain L; Gyan E; Morschhauser F; Casasnovas O; Moles MP; Michallet AS; Gressin R; Damaj G; Rose C; Sirvent A; Hermine O; Mohty M; Milpied N; Le Gouill S
Ann Hematol; 2014 Feb; 93(2):233-42. PubMed ID: 24563925
[TBL] [Abstract][Full Text] [Related]
16. Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC.
Touzeau C; Leux C; Bouabdallah R; Roussel M; Delarue R; Bouabdallah K; Thieblemont C; Cacheux V; Cartron G; Compain L; Gyan E; Morschhauser F; Casasnovas O; Moles MP; Michallet AS; Gressin R; Damaj G; Rose C; Sirvent A; Hermine O; Mohty M; Milpied N; Le Gouill S
Ann Hematol; 2014 Feb; 93(2):233-42. PubMed ID: 23949376
[TBL] [Abstract][Full Text] [Related]
17. High-dose therapy and autologous stem-cell transplantation can improve event-free survival for indolent lymphoma: a study using patients as their own controls.
Vignot S; Mounier N; Larghero J; Brice P; Quero L; de Bazelaire C; Ertault M; Brière J; Madelaine I; Gisselbrecht C
Cancer; 2007 Jan; 109(1):60-7. PubMed ID: 17111421
[TBL] [Abstract][Full Text] [Related]
18. High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival.
Kim MK; Kim S; Lee SS; Sym SJ; Lee DH; Jang S; Park CJ; Chi HS; Huh J; Suh C
Ann Hematol; 2007 Jun; 86(6):435-42. PubMed ID: 17256144
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older.
Gopal AK; Gooley TA; Golden JB; Maloney DG; Bensinger WI; Petersdorf SH; Appelbaum FR; Press OW
Bone Marrow Transplant; 2001 Mar; 27(6):593-9. PubMed ID: 11319588
[TBL] [Abstract][Full Text] [Related]
20. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation.
Peniket AJ; Ruiz de Elvira MC; Taghipour G; Cordonnier C; Gluckman E; de Witte T; Santini G; Blaise D; Greinix H; Ferrant A; Cornelissen J; Schmitz N; Goldstone AH;
Bone Marrow Transplant; 2003 Apr; 31(8):667-78. PubMed ID: 12692607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
